ApexTransGulf Manufacturing, a specialist plastics producer operating from the Salalah Free Zone, is expanding its manufacturing footprint with a RO 11.9 million investment aimed at boosting output of medical-grade plastic products.
The expansion forms part of the newly launched Ladayn Plastics Industries Programme, supported by OQ Group, and includes the installation of new production lines dedicated to healthcare applications. The investment leverages locally sourced raw materials from OQ while benefiting from Oman’s free trade agreements to serve regional and global markets.
Apex TransGulf is among nine industrial projects inaugurated at Sohar Industrial City under the Ladayn programme, which together represent total investments of around RO 40 million. Collectively, the projects are expected to generate about 200 direct jobs, alongside additional indirect employment across supply chains, supporting Oman’s industrial diversification and localisation goals.
Shayan N Sumar, Managing Director of Apex TransGulf Manufacturing, said the company has operated as a Salalah Free Zone–registered entity since 2015, focusing on polyethylene and polypropylene packaging solutions primarily for the healthcare sector.
He noted that the company was designed from the outset as an export-oriented manufacturer, serving highly regulated markets. Apex TransGulf produces Class I and Class II medical devices registered with the US Food and Drug Administration (FDA), with the United States and Europe accounting for its main export destinations.
As part of the latest expansion, Sumar said the company has doubled its production capacity in 2025 through deeper integration with OQ. Apex TransGulf currently operates 14 blown-film production lines and is adding three more, lifting monthly output from around 1,200–1,500 tonnes to approximately 2,500 tonnes.
Environmental performance and regulatory compliance remain central to the company’s strategy. Sumar highlighted that Apex TransGulf offers PFAS-free products that comply with both European and US regulations, alongside compostable alternatives made from FDA-registered resins certified as home-compostable.
He added that recyclability is embedded across the company’s product portfolio, noting that while recycled material cannot be used for critical medical applications, it can be repurposed for other grades, ensuring responsible material utilisation throughout the value chain.